文献速递胸部CT

肺癌筛查CT中疑似感染或炎性发现的真实世界使用与结局:Lung-RADS v1.1 4B类与Lung-RADS v2022 0类比较

Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT.
PubMed 文献 · AJR Am J Roentgenol · 2025-07-16

这项回顾性研究纳入2019年1月至2023年12月接受肺癌筛查CT的14,478例患者,比较Lung-RADS v1.1 4B类与v2022 0类用于疑似感染或炎性发现的真实世界使用与结局。v1.1下4B类因疑似感染或炎性发现的比例为0.4%(55/14,478),v2022下0类为0.8%(88/11,348)(p < .001)。4B类中76%良性、22%恶性、2%随访不足;0类中98%良性、无恶性、2%随访不足(p < .001)。

要点

  • v2022下0类用于疑似感染或炎性发现的比例为0.8%(88/11,348),高于v1.1下4B类的0.4%(55/14,478)(p < .001)。
  • v2022 0类检查中无恶性,v1.1 4B类中22%为恶性、76%为良性、2%随访不足(p < .001)。
  • 原发发现为磨玻璃结节/影或树芽结节者均无恶性。

核心结论

  • 对于疑似感染或炎性发现,v2022的0类使用频率高于v1.1的4B类。
  • 然而,无一例0类检查为恶性。
  • 0类标注常见于v2022提示短期随访可能并非必需的发现(即磨玻璃结节或树芽结节)。

研究设计与样本

  • 回顾性研究纳入14,478例患者(平均年龄63.2 ± 7.0岁;男7801例,女6677例),于2019年1月至2023年12月接受肺癌筛查CT,分别采用v1.1或v2022判读。
  • 通过复习放射学报告,识别因疑似感染或炎性发现而按v1.1报告为Lung-RADS 4B或按v2022报告为Lung-RADS 0的检查,并描述主要发现。
  • 依据电子病历数据和随访影像将病例分类为良性或恶性,并对Lung-RADS 4B与Lung-RADS 0检查进行比较。

关键影像表现/征象

  • Lung-RADS 4B检查的主要发现最常见为实性结节(65%)或部分实性结节(24%)。
  • Lung-RADS 0检查的主要发现最常见为磨玻璃结节/影(43%)、实性结节(25%)或树芽结节(13%)(p < .001)。

诊断标准与关键数值

  • 因疑似感染或炎性发现而归为Lung-RADS 4B的比例为0.4%(55/14,478),归为Lung-RADS 0的比例为0.8%(88/11,348)(p < .001)。
  • Lung-RADS 4B检查中76%为良性、22%为恶性、2%随访不足;Lung-RADS 0检查中98%为良性、无恶性、2%随访不足(p < .001)。
  • 主要发现为磨玻璃结节/影或树芽结节的检查均无恶性。

临床应用与阅片要点

  • 遵循Lung-RADS关于需要归为0类的疑似感染或炎性发现类型的指导,对于避免可能不必要的随访建议很重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Lung-RADS version 2022 (v2022) updated the reporting of suspected infectious/inflammatory findings warranting short-term follow-up, replacing the option in Lung-RADS version 1.1 (v1.1) to classify such findings as Lung-RADS category 4B with an option to classify such findings as Lung-RADS category 0. OBJECTIVE. The purpose of this study was to compare real-world use and outcomes of Lung-RADS v1.1 category 4B and Lung-RADS v2022 category 0 for suspected infectious/inflammatory findings on lung cancer screening (LCS) examinations. METHODS. This retrospective study included 14,478 patients (mean age, 63.2 ± 7.0 [SD] years; 7801 men, 6677 women) who underwent LCS CT from January 2019 to December 2023, interpreted using either v1.1 or v2022. Radiology reports were reviewed to identify examinations reported as Lung-RADS 4B using v1.1 or Lung-RADS 0 using v2022 due to suspected infectious/inflammatory findings and to characterize primary findings. Cases were classified as benign or malignant on the basis of EMR data and follow-up imaging. Examinations classified as Lung-RADS 4B and Lung-RADS 0 were compared. RESULTS. The frequency of Lung-RADS 4B classification due to suspected infectious/inflammatory findings using v1.1 was 0.4% (55/14,478) and Lung-RADS 0 classification due to suspected infectious/inflammatory findings using v2022 was 0.8% (88/11,348) (p < .001). The primary findings for Lung-RADS 4B examinations were most commonly solid nodule (65%) or part-solid nodule (24%) and for Lung-RADS 0 examinations were most commonly ground-glass nodule/opacity (43%), solid nodule (25%), or tree-in-bud nodules (13%) (p < .001). Of Lung-RADS 4B examinations, 76% were benign, 22% were malignant, and 2% had insufficient follow-up; of Lung-RADS 0 examinations, 98% were benign, none were malignant, and 2% had insufficient follow-up (p < .001). No examination with a primary finding of ground-glass nodule/opacity or tree-in-bud nodules was malignant. CONCLUSION. For suspected infectious/inflammatory findings, Lung-RADS 0 for v2022 was used more frequently than Lung-RADS 4B for v1.1. However, no Lung-RADS 0 examination was malignant. Lung-RADS 0 designations were commonly for findings (i.e., ground-glass or tree-in-bud nodules) for which v2022 indicates short-term follow-up may not be warranted. CLINICAL IMPACT. Adherence to Lung-RADS guidance regarding types of suspected infectious/inflammatory findings warranting Lung-RADS 0 classification is important for avoiding potentially unnecessary follow-up recommendations.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Arora S, Hammer MM, Byrne SC, et al. Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT. AJR Am J Roentgenol. 2025. PMID: 40668628. doi:10.2214/AJR.25.33279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。